Tag Archives: sunitinib

New Hope for Patients with Advanced Metastatic Colorectal Cancer Patients

Colorectal cancer is the fourth most common cancer in men and women with nearly 500,000 deaths due to colorectal cancer every year.  When detected early at localized stage I, the 5-year survival rate can reach 90%. At this stage, surgical … Continue reading

Posted in Cancer, Colorectal cancer | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

FDA Approved Afinitor for a Type of Advanced Pancreatic Cancer

The US Food and Drug Administration (FDA) has approved everolimus (Afinitor) to treat patients with advanced pancreatic neuroendocrine tumors (pNETs).  pNETs is a rare, slow-growing form of pancreatic cancer.  In theUnited States, there are fewer than 1000 new pNET cases … Continue reading

Posted in Cancer, Pancreatic Cancer | Tagged , , , , , , , , , , , , , | Leave a comment

Europe Approved Sutent for Rare Pancreatic Cancer

The European Commission has recently approved Sutent (sunitinib) as a medicine for treating patients with pancreatic neuroendocrine tumors (NET).   The drug is now indicated to treat unresectable metastatic, well-differentiated pancreatic NET in adults with disease progression.  The approval was based … Continue reading

Posted in Cancer, Pancreatic Cancer | Tagged , , , , , | Leave a comment

Everolimus (Affinitor) Improves Survival in Pancreatic Neuroendocrine Tumors

Pancreatic neuroendocrine tumors affect the hormone-producing tissues within the pancreas, and have an incidence rate, affecting only 2 to 4 people per million worldwide.   The incidence, however, is rising, and has quadrupled in the past 30 years, according to data … Continue reading

Posted in Cancer, Pancreatic Cancer | Tagged , , , , , , , , , , , , | Leave a comment